Expert Ratings for Genmab
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Genmab (NASDAQ:GMAB) stock, with an average 12-month price target of $48.75, up 4.84% from the previous average of $46.50. All 4 analysts have given bullish ratings.
June 06, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab (NASDAQ:GMAB) has received 4 bullish ratings from analysts in the past 3 months, with an average 12-month price target of $48.75, up 4.84% from the previous average.
The 4 bullish ratings from analysts indicate a positive outlook for Genmab's stock in the short term. The increase in the average 12-month price target by 4.84% from the previous average suggests that analysts have a growing confidence in the company's performance. This is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100